Hyloris Lays Out Ambitious Plans For US

Value Added Medicines Specialist Reveals How It Will Use IPO Proceeds

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Fresh from a successful IPO, Belgian value-added medicines specialist Hyloris Pharmaceuticals has the financial firepower it needs to pursue ambitious expansion plans that include building out a US commercial infrastructure, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview.

Stijin van_Rompay
Stijn Van Rompay lays out Hyloris’ strategy • Source: Hyloris

Belgium’s Hyloris Pharmaceuticals has so far enjoyed a fruitful 2020. Having kicked off the year with a funding round that raised €15m ($17.6m) for the value-added medicines developer (Also see "Hyloris Funding Round Raises €15m" - Generics Bulletin, 4 May, 2020.), the firm more recently announced an initial public offering to give it the funding it needs to pursue opportunities through the US hybrid 505(b)(2) regulatory pathway. (Also see "Value-Added Specialist Hyloris Launches IPO" - Generics Bulletin, 3 June, 2020.) This ultimately resulted in proceeds of €61.81m, or approximately €71.08m assuming the exercise in full of the IPO’s over-allotment option.

Now, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview, the firm will be able to build on...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

Neuraxpharm Enters Japanese Market 1

 
• By David Wallace

Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

Hyloris Sets Out Plans To Expand Its Pipeline

 
• By Akriti Seth

After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

Awards Offers Two Weeks Of Online Networking

 
• By David Wallace

From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

Hyloris And Purna Strike Value-Added Development Deal

 
• By David Wallace

Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.